Nanoscribe, the pioneer and market leader in high-precision additive manufacturing, strengthens its strategic position by entering the CELLINK Group. CELLINK was founded in 2016 for commercializing the world’s first universal bioink. The publicly listed company has consistently expanded its portfolio into a bioconvergence company offering solutions for bioprinting, multiomics, cell line development and diagnostics. Nanoscribe will continue developing high-precision additive manufacturing solutions as part of the CELLINK’s business area Bioprinting.
Nanoscribe to become a CELLINK company
The life science industry is currently going through a very exciting transformation where many processes and technologies are being miniaturized to increase throughput and reduce cost, where price of reagents is a major bottle neck for sequencing. One example is the sample preparation steps for single cell genomics applications. With Nanoscribe’s microfabrication technologies, the CELLINK Group stays competitive in this transformation and aims to miniaturize devices for a wide range of applications, resulting in internal capabilities to further expand its consumables offering across all business areas.
Nanoscribe’s high-precision 3D printing capabilities for life sciences and medicine
With Nanoscribe, the CELLINK Group is the world’s first life science company with internal Two-Photon Polymerization (2PP) additive manufacturing capabilities. Nanoscribe’s 2PP technology enables bioprinting of vascular microenvironments at sub-cellular scale, suitable for cell studies and lab-on-a-chip applications, which is expected to contribute to the groups’ product development, yielding additional recurring revenue through fabrication of implants, microneedles, microporous membranes, and consumables for omics applications. There are several strong synergies by combining CELLINK’s cutting-edge macro structural bioprinting technology with Nanoscribe's micro structural bioprinting technology for more realistic tissue architecture, including vascularization, cell supports. The 2PP technology will enable a cross-functional adoption within all three business areas and enhance consumables product development and offerings of the CELLINK Group. “With Nanoscribe’s state of the art 2PP technology, we will complement our product portfolio and offer a wider range of products to our amazing customers. We are combining our strong, purpose driven growth agenda with trailblazing bioconverging technologies for the sake of improving health all around the world”, emphasizes Erik Gatenholm, CEO of CELLINK.
Versatile microfabrication solutions for cutting-edge research and industrial solutions
As pioneer and a market leader in 2PP-based microfabrication technologies, Nanoscribe looks on a customer base in over 30 countries worldwide in a wide range of different sectors. “We take pride in our state-of-the-art 2PP technology, offering our customers the tools to materialize their ground-breaking ideas. We are a vibrant, award-winning company that continuously strives to maintain our market leading position, which has been achieved through close relationships with our customers”, says Martin Hermatschweiler, co-founder and CEO of Nanoscribe. Based on the expertise in 2PP-based microfabrication technologies, Nanoscribe continues to empower cutting-edge science and drives industrial innovations in a wide variety of sectors such as bioprinting, microfluidics, microoptics, micromechanics, biomedical engineering, and integrated photonics technologies. “We very much look forward to join the CELLINK Group and together explore the enormous opportunities with the 2PP technology”, Martin Hermatschweiler continues.
The medium-sized company develops and produces 3D printers and maskless lithography systems for microfabrication as well as specially developed printing materials and application-specific solution sets. The specialist for additive manufacturing of high-precision structures and objects on the nano-, micro- and mesoscale was founded in 2007 as a spin-off of the Karlsruhe Institute of Technology (KIT). More than 2,500 users and operators at top universities and innovative industrial companies worldwide benefit from the groundbreaking technology and application tailored solutions for 3D Microfabrication. Nanoscribe has created its strong market leading position through high quality engineering and agility to continuously develop its products to meet customers’ high expectations. Nanoscribe expects to diversify its product portfolio further in the near future, to expand the customer base.
Founded in 2016, CELLINK is the leading bioconvergence company in world that provides technologies, products, and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq Stockholm under CLNK B.